A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...

However, IP challenges or patent expirations will bring generic encroachment, affecting Regeneron's revenue streams. As with many healthcare companies, Regeneron faces these IP threats.

Biotech company Regeneron Pharmaceuticals lost a bid on Friday to be held immune from allegations that it misused a patented protein while testing a COVID-19 treatment.

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

In determining that Regeneron engaged in inequitable conduct, rendering the ‘018 patent unenforceable, the Court applied the Therasense standard.

Update 3:15pm: Adds Regeneron comment, updates shares. Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 4.5% after a judge denied the company's motion for a preliminary injunction to block an Amgen ...

By Connor Hart Regeneron Pharmaceuticals said it is working to determine a path forward for its treatment of several retinal conditions after the Food and Drug Administration said it didn't agree ...

Regeneron has a very strong pipeline consisting of treatments that can complement current cash cows (EYLEA and Dupixent) along with potential blockbusters.

Last week, Regeneron filed a motion to terminate IPR2023-00620, an IPR filed by Celltrion on February 28, 2023, seeking cancellation of claims 1-4 of Regeneron’s U.S. Patent No. 10,406,226 which ...

Regeneron Pharmaceuticals (NASDAQ: REGN) dropped 1.6% after the company's loss against Amgen (NASDAQ: AMGN) in a patent case over Regeneron's blockbuster Eylea drug was affirmed by an appeals court.

The Interfaith Center on Corporate Responsibility, a group of activist stakeholders, asked top drugmakers to consider patient access when they develop patent strategies.

Big Pharma is enthralled with the Amgen vs. | Big Pharma is enthralled with the Amgen vs. Sanofi PCSK9 patent fight, and for good reason: Its outcome could affect their in-development meds—and ...